Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T19:11:40.733Z.
Calculation as of: 2026-10-06T19:11:40.733Z.
Quote observation: 2026-10-06T19:10:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fb57f85ed843ad7a76bd5b785e55fde6d0feef1b4d3f081c49812093a2178ef2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$120.30M
EV/Sales Ratio
34.58x
TTM Avg
290.93x
3Y Avg
290.93x
5Y Avg
290.93x
Market Cap
$119.30M
EV/Sales Ratio
4.43x
TTM Avg
33.01x
3Y Avg
61.00x
5Y Avg
61.00x
Market Cap
$118.41M
EV/Sales Ratio
N/A
TTM Avg
52.14x
3Y Avg
28.39x
5Y Avg
28.39x
Market Cap
$125.09M
EV/Sales Ratio
N/A
TTM Avg
2.04x
3Y Avg
447.22x
5Y Avg
447.22x
Market Cap
$115.88M
EV/Sales Ratio
N/A
TTM Avg
52.04x
3Y Avg
28.07x
5Y Avg
28.07x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| enGene Holdings Inc. (ENGN) | $121.12M | N/A | N/A | N/A | N/A |
| Seer, Inc. (SEER)vs › | $121.05M | 8.47x | 5.92x | 6.73x | 48.81x |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $120.30M | 34.58x | 290.93x | 290.93x | 290.93x |
| Cibus, Inc. (CBUS)vs › | $122.13M | 30.93x | 52.83x | 97.39x | 88.07x |
| LENZ Therapeutics, Inc. (LENZ)vs › | $119.30M | 4.43x | 33.01x | 61.00x | 61.00x |
| Spruce Biosciences, Inc. (SPRB)vs › | $118.41M | N/A | 52.14x | 28.39x | 28.39x |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $125.09M | N/A | 2.04x | 447.22x | 447.22x |
| TuHURA Biosciences, Inc. (HURA)vs › | $125.14M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $115.88M | N/A | 52.04x | 28.07x | 28.07x |
| Entera Bio Ltd. (ENTX)vs › | $126.92M | N/A | 569.53x | 685.92x | 425.88x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
